Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Doctoral: Vanier Canada Graduate Scholarships

McGill University

$150,000.00

The functional complexities of macrophage ontogeny in glioblastoma outcomes

EF 2023-24

Résumé
Dr. Daniela Quail - McGill University Glioblastoma is the most common type of primary brain tumour and remains very hard to treat. Even when treated with aggressive therapies, affected patients will, on average, survive less than 15 months. One key feature of glioblastoma is the accumulation of certain immune cells called macrophages, which make the tumour more aggressive. However, some other types of macrophages are highly beneficial and can help fight cancer cells. Our recent work has shown that in glioblastoma patients who survived more than three years, tumours have an accumulation of a rare subset of beneficial macrophages that produce a protein known as myeloperoxidase. These "good-macrophages" exhibit anti-tumour properties compared to "bad-macrophages" that lack myeloperoxidase. Therefore, my research goal is to learn whether I can manipulate the development of these macrophages to favour the accumulation of "good" anti-tumour subsets. One proposed way to achieve this is by educating or training these cells at the level of the bone marrow (the factory where macrophages originate from) so they remember how to fight cancer better. This process is known as trained immunity, where trained cells exhibit stronger immune responses compared to untrained ones. Hence, one of my goals is to investigate whether good macrophages can acquire trained immunity. Moreover, by inducing changes in the bone marrow, we might be able to shift the resultant balance of good versus bad macrophages within brain tumours as well. With these goals in mind, I will analyze multiple preclinical models of glioblastoma and tumour samples from patients to investigate whether trained immunity can promote favourable macrophage development and improve survival. Overall, by understanding the development of these anti-tumoral macrophages and leveraging their ability to mediate cancer death, we can develop novel therapeutics and help glioblastoma patients live longer.
Programme
Doctoral: Vanier Canada Graduate Scholarships
Bénéficiaire
Emplacement
Quebec, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database

Tel que publié

Id
495836
Name
Atallah Aline
Region
Québec
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Cancer Research
Theme2
Biomedical
Prcname2
Vanier Canada Graduate Scholarships CIHR
Projecttitle
The functional complexities of macrophage ontogeny in glioblastoma outcomes
Programtype2
Studentship Programs
Orgnameinp2
McGill University
Cihramount2
$150,000
Cihrequipment2
$0
Programname2
Doctoral: Vanier Canada Graduate Scholarships
Keyworddelim
Cancer Immunology; Glioblastoma; Immunotherapy; Tumour Immune Microenviornment
Abstract
Dr. Daniela Quail - McGill University Glioblastoma is the most common type of primary brain tumour and remains very hard to treat. Even when treated with aggressive therapies, affected patients will, on average, survive less than 15 months. One key feature of glioblastoma is the accumulation of certain immune cells called macrophages, which make the tumour more aggressive. However, some other types of macrophages are highly beneficial and can help fight cancer cells. Our recent work has shown that in glioblastoma patients who survived more than three years, tumours have an accumulation of a rare subset of beneficial macrophages that produce a protein known as myeloperoxidase. These "good-macrophages" exhibit anti-tumour properties compared to "bad-macrophages" that lack myeloperoxidase. Therefore, my research goal is to learn whether I can manipulate the development of these macrophages to favour the accumulation of "good" anti-tumour subsets. One proposed way to achieve this is by educating or training these cells at the level of the bone marrow (the factory where macrophages originate from) so they remember how to fight cancer better. This process is known as trained immunity, where trained cells exhibit stronger immune responses compared to untrained ones. Hence, one of my goals is to investigate whether good macrophages can acquire trained immunity. Moreover, by inducing changes in the bone marrow, we might be able to shift the resultant balance of good versus bad macrophages within brain tumours as well. With these goals in mind, I will analyze multiple preclinical models of glioblastoma and tumour samples from patients to investigate whether trained immunity can promote favourable macrophage development and improve survival. Overall, by understanding the development of these anti-tumoral macrophages and leveraging their ability to mediate cancer death, we can develop novel therapeutics and help glioblastoma patients live longer.
Competitiondate
202311
Approvedterm2
3 yrs 0 mth
Pinamesdelim
Atallah, Aline
Approvedterm
3 ans 0 mois
Cihrcontribution2
~ $150,000~ $0~